The Role of High-Dose Therapy and Autologous Bone Marrow Reinfusion in the Treatment of Malignant Lymphomas

References

• Frei E, Canellos G P. Dose: A critical factor in cancer chemotherapy. Am J Med 1980; 69: 585–594
   PubMed Web of Science ®Google Scholar
• Schabel F M, Trader M W, Laster W R, et al. Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot Chemother 1978; 23: 200–215
   PubMedGoogle Scholar
• Frei E, Cucchi C A, Rosowsky A, et al. Alkylating agent resistance in vitro studies with human cell lines. Proc Natl Acad Sci (USA) 1985; 82: 2158–2162
   PubMed Web of Science ®Google Scholar
• Teicher B A, Cucchi C A, Lee J B, et al. Alkylating agents: In vitro studies of cross-resistance patterns in human cell lines. Cancer Res 1986; 46: 4379–4383
   PubMed Web of Science ®Google Scholar
• Thomas E D, Buckner C D, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation and allogenic marrow transplantation. Blood 1977; 49: 511–533
   PubMed Web of Science ®Google Scholar
• Hurd D D, Ramsay N KC, Nesbit M E, et al. Allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Blood 1983; 62(1)223a
   Google Scholar
• Applebaum F R, Thomas E D. Review of the use of marrow transplantation in the treatment of non-Hodgkin's lymphoma. J Clin Oncol 1983; 1: 440–447
   PubMed Web of Science ®Google Scholar
• Tannir N M, Spitzer G, Zander A R, et al. High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma. Eur J Cancer Clin Oncol 1983; 19: 1091–1096
   PubMedGoogle Scholar
• Herzig G P. Autologous marrow transplantation for cancer therapy. Advances in Immunobiology: Blood Cell Antigens and Bone Marrow Transplantation, J McCullough, S G Sandler. Alan R. Liss, Inc., New York 1984; 319–336
   Google Scholar
• Jacobson L O, Maries E K, Robson M J, et al. Effect of spleen protection on mortality following x-irradiation. J Lab Clin Med 1949; 34: 1538
   Web of Science ®Google Scholar
• Till J E, McCulloch E A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961; 14: 213
   PubMed Web of Science ®Google Scholar
• Thomas E D, Storb R. Technique of human marrow grafting. Blood 1970; 36: 507
   PubMed Web of Science ®Google Scholar
• Pegg D E. Bone Marrow Transplantation. Medical Yearbook Publishers, Chicago 1966
   Google Scholar
• Armitage J O, Fyfe M ME, Lewis J. Long term remission durability and functional states of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol 1984; 2: 898–902
   PubMed Web of Science ®Google Scholar
• Gaynor E R, Ultmann J E, Golomb H M, et al. Treatment of diffuse histiocytic lymphoma (DHL) and COMLA (cyclophosphamide, Oncovin, methotrexate, leukovorin, cytosine arabinoside): A 10 year experience in a single institution. J Clin Oncol 1985; 3: 1596–1604
   PubMed Web of Science ®Google Scholar
• Fisher R I, DeVita V T, Hubbard S M, et al. Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 1983; 98: 304–309
   PubMed Web of Science ®Google Scholar
• Skarin A T, Canellos G P, Rosenthal D S, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high-dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983; 1: 91–98
   PubMed Web of Science ®Google Scholar
• Klimo P, Connors J M. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Appelbaum F R, Deisseroth A B, Graw R G, et al. Prolonged and complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. Cancer 1978; 41: 1059–1063
   PubMed Web of Science ®Google Scholar
• Kaizer H, Wharam H O, Munoz L L, et al. Autologous bone marrow transplantation in the treatment of selected human malignancies: The Johns Hopkins Oncology Centre Program. Exp Hematol 1979; 7(5)309–320
   PubMedGoogle Scholar
• Spitzer G, Dicke K A, Litam J, et al. High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors. Cancer 1980; 45: 3075–3085
   PubMed Web of Science ®Google Scholar
• Douer D, Champlin R E, Ho W G, et al. High-dose combined modality therapy and autologous bone marrow transplantation in resistant cancer. Am J Med 1981; 71: 973–976
   PubMed Web of Science ®Google Scholar
• Robinson W A, Hartmaim D W, Mangalik A, et al. Autologous non-frozen bone marrow transplantation after intensive chemotherapy: A pilot study. Acta Haematol 1981; 66: 145–153
   PubMed Web of Science ®Google Scholar
• Sarna G P, Champlin R, Wells J, et al. Phase I study of high-dose mitomycin with autologous bone marrow support. Cancer Treat Rep 1982; 66: 277–282
   PubMedGoogle Scholar
• Zander A R, Spitzer G, Legha S, et al. High-dose AMSA and bone marrow rescue in patients with solid tumors. Cancer Treat Rep 1982; 66: 385–386
   PubMedGoogle Scholar
• Harada M, Yoshida T, Funada H, et al. Combined modality therapy and autologous bone marrow transplantation in the treatment of advanced non-Hodgkin's lymphoma and solid tumor: The Kanagawa experience. Transplant Proc 1982; 14: 733–737
   PubMed Web of Science ®Google Scholar
• Bensinger W, Buchner C D, Stewart P, et al. Autologous bone marrow transplantation for end-stage lymphomas. J Cell Biochem 1983; 58(Suppl 7A)
   Google Scholar
• Gorin N C, Najman A, Douay L, et al. Autologous bone marrow transplantation in the treatment of poor-prognosis non-Hodgkin's lymphoma. Eur J Cancer 1984; 20: 217–225
   Web of Science ®Google Scholar
• Lu C, Braine H G, Kaizer H, et al. Preliminary results of high-dose busulphan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer Treat Rep 1984; 68: 711–717
   PubMedGoogle Scholar
• Ricci P, Visani G, Bandini G, et al. BAVC regimen and autologous bone marrow transplantation (ABMT) in high risk non-Hodgkin's lymphoma. Exp Hematol 1984; 12(15)139–140
   PubMedGoogle Scholar
• Gulati S, Fedorciw B, Gopal A, . K A Dicke, G Spitzer, A R Zander, N C Gorin, et al. University of Texas, Houston 1985; 75–81
   Google Scholar
• Philip T, Biron P, Maraninchi D, . Massive chemotherapy with autologous bone marrow transplantation in 50 cases of non-Hodgkin's lymphoma with poor prognosis. Autologous Bone Marrow Tranplantation. Proceedings of the First International Symposium, K A Dicke, G. Spitzer, A R Zander, N C Gorin, et al. University of Texas, Houston 1985; 89–107
   Google Scholar
• Phillips G L, Wolff S N, Herzig R H, . The role of total body irradiation in the treatment of lymphoma. Autologous Bone Marrow Transplantation. Proceedings of the First International Symposium, K A Dicke, G Spitzer, A R Zander, N C Gorin, et al. University of Texas, Houston 1986; 117–123
   Google Scholar
• Santini G, Carella A M, Congiu A M, et al. Autologous non-frozen bone marrow tranplantation: Report of 16 cases. Exp Hematol 1985; 13(17)49
   PubMedGoogle Scholar
• Verdonck L F, Dekker A W, van Kempen M L, et al. Intensive cytotoxic therapy followed by autologous bone marrow transplantation for non-Hodgkin's lymphoma of high-grade malignancy. Blood 1985; 65: 984–989
   PubMed Web of Science ®Google Scholar
• Anderson C C, Goldstone A H, Souhami B L, et al. Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma. Cancer Chemother Pharmacol 1986; 16: 170–175
   PubMed Web of Science ®Google Scholar
• Armitage J O, Gingrich R D, Klassen L W, et al. Trial of high-dose cytarabine, cyclophosphamide, total-body irradiaton, and autologous marrow transplantation for refractory lymphoma. Cancer Treat Rep 1986; 20: 871–875
   Google Scholar
• Goldstone AH (for the European Bone Marrow Transplant Group). EBMT experience of autologous bone marrow transplantation in non-Hodgkin's lymphoma and Hodgkin's disease. Bone Marrow Transplant 1986; l(1)289–292
   Google Scholar
• Gorin N C, David R, Stachowiak J, et al. High-dose chemotherapy and autologous bone marrow transplantation in acute leukemias, malignant lymphomas and solid tumors A study of 23 patients. Eur J Cancer 1981; 17: 557–568
   PubMed Web of Science ®Google Scholar
• Ricci P, Bandini G, Visani G, et al. Superintensive chemotherapy and autologous bone marrow transplantation in non-Hodgkin's lymphoma. Lancet 1984; i: 686
   Google Scholar
• Longo D L, Young R C, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295–1306
   PubMed Web of Science ®Google Scholar
• Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 1982; 96: 139–143
   PubMed Web of Science ®Google Scholar
• Santoro A, Bonadonna G, Bonfante V, et al. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 1982
   PubMed Web of Science ®Google Scholar
• Phillips G L, Fay J W, Herzig G P, et al. Intensive 1,3-bis(2-chloroethylM-nitrosourea (BCNU) and cyropreserved autologous marrow transplantation for refractory cancer A phase I-II study. Cancer 1983; 52: 1792–1802
   PubMed Web of Science ®Google Scholar
• Carella A M, Santini G, Santoro A, et al. Massive chemotherapy and non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin's disease. Eur J Cancer Clin Oncol 1985; 21: 607–613
   PubMedGoogle Scholar
• Corringham R, Gilmore M, Prentice H G, et al. High-dose melphalan with autologous bone marrow transplant. Treatment of poor prognosis tumors. Cancer 1983; 52: 1783–1787
   Google Scholar
• Appelbaum F R, Herzig G, Graw R G, et al. Accelerated hemopoietic recovery following the infusion of cryopreserved autologous bone marrow in humans. Exp Hematol 1979; 7(5)297–301
   PubMedGoogle Scholar
• Philip T, Biron P, Bonfetti E, . Aggressive chemotherapy and autologous bone marrow transplantation in non-leukemic lymphomas and solid tumors. Autologous Bone Marrow Transplantation and Solid Tumors, J G McVie, O Dalesio, I E Smith, et al. Raven Press, New York 1984; 137–144
   Google Scholar
• Mazza P, Ricci P, Visani G, et al. Superintensive therapy followed by autologous bone marrow transplantation in malignant lymphomas: Bologna experience. Int J Cell Clon 1985; 3: 223
   Google Scholar
• Carella A M, Congiu A, Santini G, et al. High-dose chemotherapy (HDC) and autologous BMT in advanced highly treated Hodgkin's disease (AHT-HD). Bone Marrow Transplant 1986; 1: 293–296
   Google Scholar
• Goldstone A H, Anderson C C, Linch D C, et al. High-dose therapy with autologous bone marrow transplantation for advanced relapsed adult Hodgkin's disease. Bone Marrow Transplant 1986; 1: 297
   Google Scholar
• Jagannath S, Dicke K A, Armitage J O, et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986; 104: 163–168
   PubMed Web of Science ®Google Scholar
• Appelbaum F R, Sullivan K, Thomas E D, et al. Treatment of malignant lymphoma in 100 patients with chemoradiotherapy and marrow transplantation. Exp Hematol 1985; 13: 321
   Web of Science ®Google Scholar
• Phillips G L, Herzig R H, Lazarus H M, et al. Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow. N Engl J Med 1984; 310: 1557–1561
   PubMed Web of Science ®Google Scholar
• Phillips G L, Wolff S, Herzig G, et al. Local radiotherapy followed by cyclophosphamide, fractionated total body irradiation and autologous marrow transplantation for refractory malignant lymphoma. Blood 1983; 62(1)228a
   Google Scholar
• Bast R C, Defabritius P, Lipton J, et al. Elimination of malignant clonogenic ceils from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 1985; 45: 499–503
   PubMed Web of Science ®Google Scholar
• Filipovich A H, Vallera D A, Youle R J, . Marrow purging with immunotoxins in allogeneic and autologous bone marrow transplantation: Pilot clinical studies. Autologous Bone Marrow Transplantation: Proceedings of the First International Symposium, K A Dicke, G Spitzer, A R Zander, N C Gorin, et al. University of Texas, Houston 1985; 403–408
   Google Scholar
• Arnon R, Sela M. In vitro and in vivo efficacy of conjugates of daunomycin with ami tumor antibodies. Immunol Rev 1982; 62: 5–28
   PubMed Web of Science ®Google Scholar
• Dicke K A, Poynten C A, Reading A. Elimination of leukaemic cells from remission marrow suspensions by an immunomagnetic procedure. Minimal Residual Disease in Acute Leukaemia, B Lowenberg, A Hagenbeek. Martinus Nijhoff, The Hague 1985; 209–221
   Google Scholar
• Gee A P, Graham-Pole J, Boyle M DP. Purging bone marrow for autologous transplantation: Are methods for monitoring the elimination of tumor cells reliable?. Exp Hematol 1983; II(14)7
   Google Scholar
• Le Bien T W, Stepan D E, Bartholomew R M, et al. Utilization of a colony assay to assess the variables influencing elimination of leukaemic cells from human bone marrow with monoclonal antibodies and complement. Blood 1985; 65: 945–950
   PubMed Web of Science ®Google Scholar
• Kaizer H, Wharam M D, Johnson R J, et al. Requirements for the successful application of autologous bone marrow transplantation in the treatment of selected malignancies. Hamatol Blut Transfus 1980; 25: 285–296
   PubMedGoogle Scholar
• Hurd D D, Le Biene T W, Peterson B A, et al. Intensive therapy and autologous bone marrow support (ABMS) for the treatment of refractory non-Hodgkin's lymphoma (abstr). J Cell Biochem 1986; 10D: 256
   Google Scholar
• Santos G W, Kaizer H. In vitro chemotherapy as a prelude to autologous bone marrow transplantation in haematological malignancy. Minimal Residual Disease in Acute Leukemia, B Lowenberg, A Hagenbeek. Martinus Nijhoff, Boston 1984; 165–181
   Google Scholar
• Rizzoli V, Mangoni L, Degliantoni G, et al. In vitro purging with Asta-Z of autologous bone marrow transplantation in adult leukaemia and lymphoma. Exp Hematol 1986; 13(17)44–45
   Google Scholar